MENLO PARK, CA (BUSINESS WIRE) September 15, 2015—Optivia Biotechnology Inc., a leading global provider of high-quality transporter assay services and innovative transporter research solutions, announces the launch of its Opti-Target™ Transporter Screening Panel. The new panel will assist in the discovery and development of new classes of transporter-targeted therapeutics; including CNS disorders, oncology, and metabolic diseases. It also aids researchers in adopting a transporter-conscious strategy to improve drug response and safety.
Transporters are a class of over 400 membrane proteins that tightly regulate cross-membrane transport of nutrients, signaling molecules, and xenobiotics. Transporters play a critical role in drug response and toxicity, which has led to an increase in regulatory requests for assessing transporter mediated drug-drug interactions (DDIs). Aberrant transporter activity leads to or is associated with a variety of diseases, including cancer, neurological disorders, and diabetes. Therefore, rational design of transporter-targeting molecules represents an enormous opportunity for developing new therapeutic and diagnostic agents with a novel mechanism of action and improved efficacy and safety. This is evidenced by an increasing number of approved and experimental drugs and diagnostic agents that act on various transporters, such as sertraline (depression), canagliflozin (diabetes), ivacaftor (cystic fibrosis), lesinurad (gout,) and 18F-FDG (cancer imaging).
“Transporters are key regulators of many fundamental physiological pathways,” stated Yong Huang, Ph.D., Optivia’s president and CEO. “Their strong association with the etiology and progression of numerous diseases, rare and common, make transporters attractive diagnostic biomarkers and therapeutic targets.”
The Opti-Target™ transporter panel, the first and largest of its kind, consists of nearly 40 clinically validated and novel targets implicated in both diseases and drug toxicity. Instead of indirect binding tests, Optivia’s cell-based assays measure transporters’ functional activity, which produces more reliable and biologically relevant results. These robust assays have been used extensively in discovering novel transporter modulators in multiple NIH-funded large screening campaigns. Complemented by Optivia’s popular DDI and ADME assays, the Opti-Target™ Transporter Screening Panel will further support pharmaceutical companies in developing new therapeutics using novel transporter-targeting strategies.
“Lack of appropriate assays is a major bottleneck in transporter research,” added Dr. Huang. “We are pleased to offer reliable and affordable screening services to make it easier for scientists to progress through to exciting new therapeutics.”
About Optivia Biotechnology Inc.
Since bringing the first full panel of FDA- and EMA- compliant transporter drug-drug interaction (DDI) assays to market, Optivia has been the leading provider of high-quality transporter assay services. Optivia is a thought leader in expanding the utility of transporter research in areas as diverse as pharmacokinetics, toxicology, therapeutic target discovery, and basic biology research. With the world’s largest portfolio of transporter assays, novel multi-transporter models, and customized molecular transport research solutions, Optivia is committed to understanding the complex drug transport processes for improving drug safety and efficacy.